Benzinga | Sep 29, 2020 08:47AM EDT

Roth Capital Reiterates Buy on Ligand Pharmaceuticals, Raises Price Target to $195

Roth Capital analyst Scott Henry reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $190 to $195.Roth Capital analyst Scott Henry reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $190 to $195.